Clinical trial Recruiting at 1 site Observational Ages 18 to 90

Assessing IL-17 levels in patients with spondyloarthritis

Official title: Feasibility of an Il-17a Assay and Impact on Therapeutic Response in Patients With Active Axial Spondyloarthritis

Run by Centre Hospitalier Universitaire de Nice · NCT05592574 · Data updated 2026-11-12

This study is testing if measuring IL-17 levels in patients with active spondyloarthritis can help doctors choose the best biological treatment after other medications haven't worked.

More Spondylarthritis trials

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment50 (estimated)
SponsorCentre Hospitalier Universitaire de Nice
Academic / other
Drugs / interventionsmethotrexate
Locations1 site (Nice)
StatusRecruiting
StartedFebruary 1, 2021
Main results expectedJanuary 31, 2041
Study endsJanuary 31, 2041
Registry record updatedOctober 24, 2022
Trial IDNCT05592574 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients with active spondyloarthritis who have not responded to at least two NSAIDs and meet the ASAS criteria.

Probably not a fit

Patients with predominant axial manifestations or those who have previously received biological treatments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the feasibility of measuring IL-17 cytokine levels in patients with active spondyloarthritis (axSpA) who require biological treatment after failing at least two non-steroidal anti-inflammatory drugs (NSAIDs). By stimulating immune cells and analyzing cytokine responses, the study seeks to develop a tool that could assist clinicians in selecting the most appropriate biologic therapy for these patients. The study focuses on patients meeting the ASAS criteria for spondyloarthritis and aims to address the lack of validated biomarkers in this area.

Why it matters

Potential benefit: If successful, this study could provide a valuable tool for clinicians to make more informed decisions regarding biologic treatments for patients with spondyloarthritis.

How similar studies have gone: While there have been head-to-head studies comparing biologics in related conditions, this specific approach to cytokine measurement in spondyloarthritis is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria

* Patients with spondyloarthritis meeting the ASAS criteria
* Patients who were to benefit from the implementation of a biological treatment after failure of at least two NSAIDs.
* Patients having an active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) higher than four,

Exclusion criteria

* No predominant axial manifestation,
* Having received a previous biological treatment
* Patients presenting contraindication to the implementation of these treatments.

Where it's running

  • CHU de NICE
    Nice, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.